Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force
Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.
You may also be interested in...
Signal Pharmaceuticals has chosen to accept an acquisition offer from Celgene instead of going through with an initial public offering, the companies said in a June 30 analysts call announcing the merger.
Thalomid sales representatives have disseminated third-party press releases that promote off-label use of the thalidomide capsules for multiple myeloma, an FDA warning letter to Celgene states.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011